glp-1 drugs retatrutide for weight loss: Study shows 30% body weight loss Retatrutide—A Game Changer in Obesity

Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity

About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds.

Scientists have now created long-lasting GLP-1 drugs that can be used to treat type 2 diabetes, obesity, and a range of other conditions

Learn what Toujeo actually is, how insulin glargine differs from GLP-1 agonists like semaglutide, and why the distinction matters.

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020

Delve into the perspectives of employers and health plans on obesity, GLP-1 coverage rates, and concerns about off-label use.